Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV on Any Antiretroviral Therapy Regimen: The Retrospective ESSENTIAL Study.

Infectious diseases and therapy·2026
Same author

A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians).

JAC-antimicrobial resistance·2026
Same author

Defining Success and Failure In Prosthetic Joint Infections: A Meta-epidemiologic Study Toward A Core Outcome Set.

Open forum infectious diseases·2026
Same author

Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemic.

BMJ public health·2026
Same author

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
Same author

Fever in a palliative care setting: Clinical insights and implications from a prospective observational cohort study.

Palliative medicine·2026

Related Experiment Video

Updated: Jul 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Extreme Cardiovascular Risk and LDL-C Target Achievement in People With HIV.

Andrea Giacomelli1,2, Anna Lisa Ridolfo1, Letizia Oreni1

  • 1Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.

Open Forum Infectious Diseases
|July 10, 2026
PubMed
Summary
This summary is machine-generated.

Many people with HIV and existing atherosclerotic cardiovascular disease (ASCVD) face extreme cardiovascular risk. Achieving low-density lipoprotein cholesterol (LDL-C) targets remains a challenge, hindering effective secondary prevention strategies.

Keywords:
HIVLDLcardiovascular riskguidelinestarget achievement

Related Experiment Videos

Last Updated: Jul 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • A significant number of individuals with human immunodeficiency virus (HIV) also have established atherosclerotic cardiovascular disease (ASCVD).
  • This population often meets criteria for extreme cardiovascular risk, necessitating aggressive management.
  • Current management of low-density lipoprotein cholesterol (LDL-C) in this cohort is frequently suboptimal.

Purpose of the Study:

  • To highlight the critical gap between current clinical practice and updated guideline recommendations for managing cardiovascular risk in people with HIV.
  • To emphasize the need for improved strategies to achieve lipid targets and reduce ASCVD events in this high-risk group.

Main Methods:

  • Review of current clinical guidelines for ASCVD risk management.
  • Analysis of real-world data on LDL-C target achievement in people with HIV and ASCVD.
  • Identification of barriers to optimal lipid management.

Main Results:

  • A substantial proportion of people with HIV and ASCVD do not achieve recommended LDL-C targets.
  • Suboptimal LDL-C control is a significant barrier to secondary ASCVD prevention in this population.
  • There is a marked gap between guideline recommendations and actual clinical practice.

Conclusions:

  • Urgent interventions are required to bridge the gap between guideline recommendations and real-world practice for managing cardiovascular risk in people with HIV.
  • Improving LDL-C target achievement is crucial for reducing recurrent ASCVD events in this vulnerable population.
  • Enhanced clinical strategies are essential for optimizing secondary prevention in HIV-infected individuals with established ASCVD.